Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RENASCENT III: First in Human Evaluation of the Novel Thin Strut MAGNITUDE Sirolimus-Eluting Ultra-High Molecular Weight MAGNITUDE Bioresorbable Scaffold: 9-Month Imaging and 2-Year Clinical Results.
Ferrone M, Chieffo A, Khawaja SA, Moncada M, Colombo A, Latib A, Esposito G, Stabile E, Avvedimento M, Bedogni F, Testa L, Delgado JA, Arana C, Vesga B, Cortese B, Mahera A, Granada JF. Ferrone M, et al. Among authors: arana c. Circ Cardiovasc Interv. 2021 May;14(5):e010013. doi: 10.1161/CIRCINTERVENTIONS.120.010013. Epub 2021 May 18. Circ Cardiovasc Interv. 2021. PMID: 34003665 No abstract available.
Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study.
Vesga B, Hernandez H, Moncada M, Gasior P, Higuera S, Dager A, Arana C, Delgado JA, Généreux P, Maehara A, Granada JF. Vesga B, et al. Among authors: arana c. Coron Artery Dis. 2017 Mar;28(2):126-134. doi: 10.1097/MCA.0000000000000453. Coron Artery Dis. 2017. PMID: 27879518
First in human evaluation of a novel Sirolimus-eluting ultra-high molecular weight bioresorbable scaffold: 9-, 24-and 36-months imaging and clinical results from the multi-center RENASCENT study.
Chieffo A, Khawaja SA, Vesga B, Hernandez H, Moncada M, Delgado JA, Esposito G, Ferrone M, Dager A, Arana C, Stabile E, Meliga E, De Benedictis M, Montorfano M, Latib A, Fonseca J, Gomez G, Tamburino C, Tarantini G, La Manna A, Maehara A, Granada JF, Colombo A. Chieffo A, et al. Among authors: arana c. Int J Cardiol. 2020 Dec 15;321:48-53. doi: 10.1016/j.ijcard.2020.08.014. Epub 2020 Aug 15. Int J Cardiol. 2020. PMID: 32810542
Long-term use of ticagrelor in patients with prior myocardial infarction.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Bonaca MP, et al. N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14. N Engl J Med. 2015. PMID: 25773268 Free article. Clinical Trial.
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann DL, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, East C, Fernandez A, Jering K, Landmesser U, Mehran R, Merkely B, Vaghaiwalla Mody F, Petrie MC, Petrov I, Schou M, Senni M, Sim D, van der Meer P, Lefkowitz M, Zhou Y, Gong J, Braunwald E; PARADISE-MI Investigators and Committees. Pfeffer MA, et al. N Engl J Med. 2021 Nov 11;385(20):1845-1855. doi: 10.1056/NEJMoa2104508. N Engl J Med. 2021. PMID: 34758252 Clinical Trial.
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, Shi V, Zhao Z, Cowie MR; PARALLAX Investigators and Committee members. Pieske B, et al. JAMA. 2021 Nov 16;326(19):1919-1929. doi: 10.1001/jama.2021.18463. JAMA. 2021. PMID: 34783839 Free PMC article. Clinical Trial.
Tacrolimus's Time Below Therapeutic Range Is Associated With Acute Pancreatic Graft Rejection and the Development of De Novo Donor-specific Antibodies.
Rodríguez-Espinosa D, Broseta JJ, Montagud-Marrahí E, Arana C, Ferrer J, Cuatrecasas M, Garcia-Criado Á, Amor AJ, Diekmann F, Ventura-Aguiar P. Rodríguez-Espinosa D, et al. Among authors: arana c. Transpl Int. 2024 Apr 17;37:12591. doi: 10.3389/ti.2024.12591. eCollection 2024. Transpl Int. 2024. PMID: 38694489 Free PMC article.
82 results